Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease

Nadia L. Mitchell, Katharina N. Russell, Martin P. Wellby, Hollie E. Wicky, Lucia Schoderboeck, Graham K. Barrell, Tracy R. Melzer, Steven J. Gray, Stephanie M. Hughes, David N. Palmer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are neurodegenerative lysosomal storage diseases predominantly affecting children. Single administration of brain-directed lentiviral or recombinant single-stranded adeno-associated virus 9 (ssAAV9) vectors expressing ovine CLN5 into six pre-clinically affected sheep with a naturally occurring CLN5 NCL resulted in long-term disease attenuation. Treatment efficacy was demonstrated by non-invasive longitudinal in vivo monitoring developed to align with assessments used in human medicine. The treated sheep retained neurological and cognitive function, and one ssAAV9-treated animal has been retained and is now 57 months old, almost triple the lifespan of untreated CLN5-affected sheep. The onset of visual deficits was much delayed. Computed tomography and MRI showed that brain structures and volumes remained stable. Because gene therapy in humans is more likely to begin after clinical diagnosis, self-complementary AAV9-CLN5 was injected into the brain ventricles of four 7-month-old affected sheep already showing early clinical signs in a second trial. This also halted disease progression beyond their natural lifespan. These findings demonstrate the efficacy of CLN5 gene therapy, using three different vector platforms, in a large animal model and, thus, the prognosis for human translation. Few treatments exist for the fatal inherited neurodegenerative disorder Batten disease. Here Mitchell et al. use in vivo methods to demonstrate that intracerebroventricular delivery of CLN5 gene therapy to sheep with a CLN5 form of Batten disease preserves brain structure and function and clinically stabilizes the disease.

Original languageEnglish (US)
JournalMolecular Therapy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Genetic Therapy
Sheep
Dependovirus
Brain
Lysosomal Storage Diseases
Neurodegenerative Diseases
Cognition
Disease Progression
Animal Models
Tomography
Medicine

Keywords

  • AAV and lentiviral gene therapy
  • in vivo monitoring
  • maze testing
  • NCLs
  • neuronal ceroid lipofuscinosis
  • sheep brain CT and MRI
  • sheep neurological scoring

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Mitchell, N. L., Russell, K. N., Wellby, M. P., Wicky, H. E., Schoderboeck, L., Barrell, G. K., ... Palmer, D. N. (Accepted/In press). Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2018.07.015

Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease. / Mitchell, Nadia L.; Russell, Katharina N.; Wellby, Martin P.; Wicky, Hollie E.; Schoderboeck, Lucia; Barrell, Graham K.; Melzer, Tracy R.; Gray, Steven J.; Hughes, Stephanie M.; Palmer, David N.

In: Molecular Therapy, 01.01.2018.

Research output: Contribution to journalArticle

Mitchell, Nadia L. ; Russell, Katharina N. ; Wellby, Martin P. ; Wicky, Hollie E. ; Schoderboeck, Lucia ; Barrell, Graham K. ; Melzer, Tracy R. ; Gray, Steven J. ; Hughes, Stephanie M. ; Palmer, David N. / Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease. In: Molecular Therapy. 2018.
@article{d3fc653eea564a509b8b345b93a3d8d4,
title = "Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease",
abstract = "Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are neurodegenerative lysosomal storage diseases predominantly affecting children. Single administration of brain-directed lentiviral or recombinant single-stranded adeno-associated virus 9 (ssAAV9) vectors expressing ovine CLN5 into six pre-clinically affected sheep with a naturally occurring CLN5 NCL resulted in long-term disease attenuation. Treatment efficacy was demonstrated by non-invasive longitudinal in vivo monitoring developed to align with assessments used in human medicine. The treated sheep retained neurological and cognitive function, and one ssAAV9-treated animal has been retained and is now 57 months old, almost triple the lifespan of untreated CLN5-affected sheep. The onset of visual deficits was much delayed. Computed tomography and MRI showed that brain structures and volumes remained stable. Because gene therapy in humans is more likely to begin after clinical diagnosis, self-complementary AAV9-CLN5 was injected into the brain ventricles of four 7-month-old affected sheep already showing early clinical signs in a second trial. This also halted disease progression beyond their natural lifespan. These findings demonstrate the efficacy of CLN5 gene therapy, using three different vector platforms, in a large animal model and, thus, the prognosis for human translation. Few treatments exist for the fatal inherited neurodegenerative disorder Batten disease. Here Mitchell et al. use in vivo methods to demonstrate that intracerebroventricular delivery of CLN5 gene therapy to sheep with a CLN5 form of Batten disease preserves brain structure and function and clinically stabilizes the disease.",
keywords = "AAV and lentiviral gene therapy, in vivo monitoring, maze testing, NCLs, neuronal ceroid lipofuscinosis, sheep brain CT and MRI, sheep neurological scoring",
author = "Mitchell, {Nadia L.} and Russell, {Katharina N.} and Wellby, {Martin P.} and Wicky, {Hollie E.} and Lucia Schoderboeck and Barrell, {Graham K.} and Melzer, {Tracy R.} and Gray, {Steven J.} and Hughes, {Stephanie M.} and Palmer, {David N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ymthe.2018.07.015",
language = "English (US)",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease

AU - Mitchell, Nadia L.

AU - Russell, Katharina N.

AU - Wellby, Martin P.

AU - Wicky, Hollie E.

AU - Schoderboeck, Lucia

AU - Barrell, Graham K.

AU - Melzer, Tracy R.

AU - Gray, Steven J.

AU - Hughes, Stephanie M.

AU - Palmer, David N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are neurodegenerative lysosomal storage diseases predominantly affecting children. Single administration of brain-directed lentiviral or recombinant single-stranded adeno-associated virus 9 (ssAAV9) vectors expressing ovine CLN5 into six pre-clinically affected sheep with a naturally occurring CLN5 NCL resulted in long-term disease attenuation. Treatment efficacy was demonstrated by non-invasive longitudinal in vivo monitoring developed to align with assessments used in human medicine. The treated sheep retained neurological and cognitive function, and one ssAAV9-treated animal has been retained and is now 57 months old, almost triple the lifespan of untreated CLN5-affected sheep. The onset of visual deficits was much delayed. Computed tomography and MRI showed that brain structures and volumes remained stable. Because gene therapy in humans is more likely to begin after clinical diagnosis, self-complementary AAV9-CLN5 was injected into the brain ventricles of four 7-month-old affected sheep already showing early clinical signs in a second trial. This also halted disease progression beyond their natural lifespan. These findings demonstrate the efficacy of CLN5 gene therapy, using three different vector platforms, in a large animal model and, thus, the prognosis for human translation. Few treatments exist for the fatal inherited neurodegenerative disorder Batten disease. Here Mitchell et al. use in vivo methods to demonstrate that intracerebroventricular delivery of CLN5 gene therapy to sheep with a CLN5 form of Batten disease preserves brain structure and function and clinically stabilizes the disease.

AB - Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are neurodegenerative lysosomal storage diseases predominantly affecting children. Single administration of brain-directed lentiviral or recombinant single-stranded adeno-associated virus 9 (ssAAV9) vectors expressing ovine CLN5 into six pre-clinically affected sheep with a naturally occurring CLN5 NCL resulted in long-term disease attenuation. Treatment efficacy was demonstrated by non-invasive longitudinal in vivo monitoring developed to align with assessments used in human medicine. The treated sheep retained neurological and cognitive function, and one ssAAV9-treated animal has been retained and is now 57 months old, almost triple the lifespan of untreated CLN5-affected sheep. The onset of visual deficits was much delayed. Computed tomography and MRI showed that brain structures and volumes remained stable. Because gene therapy in humans is more likely to begin after clinical diagnosis, self-complementary AAV9-CLN5 was injected into the brain ventricles of four 7-month-old affected sheep already showing early clinical signs in a second trial. This also halted disease progression beyond their natural lifespan. These findings demonstrate the efficacy of CLN5 gene therapy, using three different vector platforms, in a large animal model and, thus, the prognosis for human translation. Few treatments exist for the fatal inherited neurodegenerative disorder Batten disease. Here Mitchell et al. use in vivo methods to demonstrate that intracerebroventricular delivery of CLN5 gene therapy to sheep with a CLN5 form of Batten disease preserves brain structure and function and clinically stabilizes the disease.

KW - AAV and lentiviral gene therapy

KW - in vivo monitoring

KW - maze testing

KW - NCLs

KW - neuronal ceroid lipofuscinosis

KW - sheep brain CT and MRI

KW - sheep neurological scoring

UR - http://www.scopus.com/inward/record.url?scp=85050858807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050858807&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.07.015

DO - 10.1016/j.ymthe.2018.07.015

M3 - Article

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

ER -